Nova Measuring Instruments Ltd. - Ordinary Shares (NVMI) News
Filter NVMI News Items
NVMI News Results
|Loading, please wait...|
NVMI News Highlights
- For NVMI, its 30 day story count is now at 10.
- Over the past 15 days, the trend for NVMI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about NVMI are NOVA, EYE and OPT.
Latest NVMI News From Around the Web
Below are the latest news stories about Nova Ltd that investors may wish to consider to help them evaluate NVMI as an investment opportunity.
Nova (Nasdaq: NVMI) today announced financial results for the fourth quarter and full year 2021.
Nova (Nasdaq: NVMI) today announced the establishment of its new Chinese local corporate entity and the opening of a new Chinese headquarters in Shanghai. Nova's business in China has grown significantly in recent years, serving the expansion of the regional semiconductor industry. The new facility is part of Nova's strategy to strengthen its global sites to tighten customers' partnerships and support company's continued expansion in the region.
Nova Measuring Instruments (NVMI) fourth-quarter 2021 performance is likely to have benefited from the robust demand of its expanding product portfolio across all main product lines.
Nova (Nasdaq: NVMI) announced today its metrology portfolio for advanced gate-all-around (GAA). To enhance its market-leading portfolio, the Company is unveiling multiple advanced solutions uniquely equipped to address the manufacturing challenges of next-generation logic devices.
The stock market has gotten off to a rough start in 2022. Growth stocks -- and tech stocks in particular -- have underperformed. The VanEck Vectors Semiconductor ETF (NASDAQ: SMH) has pulled back 13.9% in 2022 after bagging a 41.9% return in 2021.
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV – a subtype of AMD, prevalent among Asian populations with high unmet medical need MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea L
MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. The presentation will be available beginning Thursday, February 1
Nova (Nasdaq: NVMI) announced today that ancosys' chemical-metrology solution was recently selected by an additional front-end wafer fabrication customer. To date, ancosys' ancolyzer® has been selected by five leading front-end wafer manufacturers, including a world-leading foundry. The newest selection of ancosys' chemical metrology solutions by leading customers indicates the significant growth in ancosys' front-end business.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022. Professor Gemmy Cheung will present data from patients with polypoidal choroidal vasculo